Literature DB >> 12625522

Quality of life in patients of nasopharyngeal carcinoma: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and the EORTC QLQ-H&N35.

W C Chie1, R L Hong, C C Lai, L L Ting, M M Hsu.   

Abstract

The authors followed the guidelines of translation and pilot testing of the EORTC QLQ-C30 and EORTC-QLQ-H&N35 questionnaires. The questionnaires were given to 50 nasopharyngeal carcinoma patients under active treatment and 50 under follow-up at our institution from November 2000 to June 2001. A retest was conducted 2 weeks after the first interview/form completion for the follow-up group. The intraclass correlation coefficients of the two questionnaires were moderate to high in the follow-up group. Cronbach's alpha coefficients of all scales of the two questionnaires were > or = 0.70 except that of cognitive functioning. Correlation of scales measuring similar dimensions of the QLQ-C30 and the SF-36 were moderate to high, while that of the QLQ-H&N35 and the QLQ-C30 and the SF-36 were moderate to low. Patients in the active treatment group had more serious acute problems due to disease and chemotherapy. Patients in the follow-up group had more serious chronic problems due to radiation therapy. We concluded that the Taiwan Chinese version of the EORTC QLQ-C30 and the EORTC QLQ-H&N35 had moderate to high test-retest reliability, high internal consistency in most scales, and could show the expected differences between patients in active treatment and follow-up group.

Entities:  

Mesh:

Year:  2003        PMID: 12625522     DOI: 10.1023/a:1022070220328

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  13 in total

1.  Psychometric evaluation of a Chinese (Taiwanese) version of the SF-36 health survey amongst middle-aged women from a rural community.

Authors:  J L Fuh; S J Wang; S R Lu; K D Juang; S J Lee
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

2.  Cigarette smoking, alcohol consumption and risk of nasopharyngeal carcinoma in Taiwan.

Authors:  Y J Cheng; A Hildesheim; M M Hsu; I H Chen; L A Brinton; P H Levine; C J Chen; C S Yang
Journal:  Cancer Causes Control       Date:  1999-06       Impact factor: 2.506

3.  A cross-validation of the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer.

Authors:  K Kobayashi; F Takeda; S Teramukai; I Gotoh; H Sakai; S Yoneda; Y Noguchi; H Ogasawara; K Yoshida
Journal:  Eur J Cancer       Date:  1998-05       Impact factor: 9.162

4.  Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement.

Authors:  M Groenvold; M C Klee; M A Sprangers; N K Aaronson
Journal:  J Clin Epidemiol       Date:  1997-04       Impact factor: 6.437

5.  Measurement of the quality of life during different clinical phases of breast cancer.

Authors:  W C Chie; C S Huang; J H Chen; K J Chang
Journal:  J Formos Med Assoc       Date:  1999-04       Impact factor: 3.282

6.  A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group.

Authors:  K Bjordal; A de Graeff; P M Fayers; E Hammerlid; C van Pottelsberghe; D Curran; M Ahlner-Elmqvist; E J Maher; J W Meyza; A Brédart; A L Söderholm; J J Arraras; J S Feine; H Abendstein; R P Morton; T Pignon; P Huguenin; A Bottomly; S Kaasa
Journal:  Eur J Cancer       Date:  2000-09       Impact factor: 9.162

7.  Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35.

Authors:  K Bjordal; E Hammerlid; M Ahlner-Elmqvist; A de Graeff; M Boysen; J F Evensen; A Biörklund; J R de Leeuw; P M Fayers; M Jannert; T Westin; S Kaasa
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

8.  Psychometric validation of the EORTC Core Quality of Life Questionnaire, 30-item version and a diagnosis-specific module for head and neck cancer patients.

Authors:  K Bjordal; S Kaasa
Journal:  Acta Oncol       Date:  1992       Impact factor: 4.089

9.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

10.  Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire.

Authors:  M J Hjermstad; S D Fossa; K Bjordal; S Kaasa
Journal:  J Clin Oncol       Date:  1995-05       Impact factor: 44.544

View more
  28 in total

1.  Prognostic value of quality of life measured after treatment on subsequent survival in patients with nasopharyngeal carcinoma.

Authors:  Wen-Ling Tsai; Chih-Yen Chien; Hsuan-Ying Huang; Kuan-Cho Liao; Fu-Min Fang
Journal:  Qual Life Res       Date:  2012-06-06       Impact factor: 4.147

2.  Further evaluation of the EORTC QLQ-C30 psychometric properties in a large Brazilian cancer patient cohort as a function of their educational status.

Authors:  Carlos Eduardo Paiva; Estela Cristina Carneseca; Eliane Marçon Barroso; Mayara Goulart de Camargos; Ana Camila Callado Alfano; Fernanda Capella Rugno; Bianca Sakamoto Ribeiro Paiva
Journal:  Support Care Cancer       Date:  2014-03-21       Impact factor: 3.603

Review 3.  Performance of the EORTC questionnaire for the assessment of quality of life in head and neck cancer patients EORTC QLQ-H&N35: a methodological review.

Authors:  Susanne Singer; Juan Ignacio Arraras; Wei-Chu Chie; Sheila E Fisher; Razvan Galalae; Eva Hammerlid; Ourania Nicolatou-Galitis; Claudia Schmalz; Irma Verdonck-de Leeuw; Eva Gamper; Judith Keszte; Dirk Hofmeister
Journal:  Qual Life Res       Date:  2012-11-28       Impact factor: 4.147

4.  The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-c30): validation of English version in Singapore.

Authors:  N Luo; C S L Fones; S E Lim; F Xie; J Thumboo; S C Li
Journal:  Qual Life Res       Date:  2005-05       Impact factor: 4.147

5.  Quality of life for head and neck cancer patients treated by combined modality therapy: the therapeutic benefit of technological advances in radiotherapy.

Authors:  Tai-Lin Huang; Wen-Ling Tsai; Chih-Yen Chien; Tsair-Fwu Lee; Fu-Min Fang
Journal:  Qual Life Res       Date:  2010-06-11       Impact factor: 4.147

6.  Sustained improvement of quality of life for nasopharyngeal carcinoma treated by intensity modulated radiation therapy in long-term survivors.

Authors:  Tao Song; Ming Fang; Xue-Bang Zhang; Ping Zhang; Rui-Fei Xie; Shi-Xiu Wu
Journal:  Int J Clin Exp Med       Date:  2015-04-15

7.  Development and validation of the simplified Chinese version of EORTC QLQ-H&N35 for patients with head and neck cancer.

Authors:  Zheng Yang; Qiong Meng; Jiahong Luo; Qian Lu; Xiaojiang Li; Gaofeng Li; Chonghua Wan
Journal:  Support Care Cancer       Date:  2011-08-18       Impact factor: 3.603

8.  A patient-reported outcome instrument to assess the impact of oropharyngeal mucositis on health-related quality of life: a longitudinal psychometric evaluation.

Authors:  Karis K F Cheng; S F Leung; Raymond H S Liang; Josepha W M Tai; Rebecca M W Yeung; David R Thompson
Journal:  Support Care Cancer       Date:  2008-08-02       Impact factor: 3.603

9.  Quality of life of lung cancer patients: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13.

Authors:  Wei-Chu Chie; Chih-Hsin Yang; Chiun Hsu; Pan-Chyr Yang
Journal:  Qual Life Res       Date:  2004-02       Impact factor: 4.147

10.  Quality of life in cancer patients in South Asia: psychometric properties of the Sinhala version of the EORTC QLQ-C30 in cancer patients with heterogeneous diagnoses.

Authors:  Harindra Jayasekara; Lalini C Rajapaksa; Neil K Aaronson
Journal:  Qual Life Res       Date:  2008-04-22       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.